摘要
目的:研究中性粒细胞/淋巴细胞比值(neutrophil/lymplocyte ratio,NLR)、血小板/淋巴细胞比值(platelet/lymphocyte ratio,PLR)对弥漫大B细胞淋巴瘤预后的影响及其预测价值。方法:回顾性分析了安徽医科大学第一附属医院57例经过化疗的弥漫大B细胞淋巴瘤患者的临床资料,根据患者工作特征曲线(ROC曲线)确定NLR和PLR的截断点,并根据初次化疗前NLR和PLR将患者分为高比值组和低比值组,采用单因素分析和COX回归多因素分析比较两组患者的总生存和无进展生存。结果:通过ROC曲线,计算出NLR和PLR的最佳截断点分别为2.915和270.27。单因素分析显示,IPI评分、NLR、PLR对患者的总生存和无进展生存均有影响。此外,结外受累数量、疾病分期、ECOG评分对疾病的无进展生存有影响。然而,多因素分析显示,仅NLR是影响患者总生存和无进展生存的独立预后因素,PLR是影响患者无进展生存的独立预后因素,但并不影响总生存。结论:初诊时NLR和PLR值可预测弥漫大B细胞淋巴瘤患者的预后。
Objective:To investigate the predictive value of neutrophil/lymphocyte ratio(NLR) and platelet/lymphocyte ratio(PLR) for the patients with diffuse large B-cell lymphoma(DLBCL).Methods:The clinical data of57 DLBCL patients admitted in the First Affiliated hospital of Anhui Medical University were analyzed retrospectively.According to ROC curve,the cut-off value for NLR and PLR was deterimined,and the patients were divided into high and low NLR/PLR groups before first chamotherapy.Then the relation of NLR and PLR with overall survival(OS) and progression-free survival(PFS) was analyzed by univariate and multivariate COX regression.Results:The optimal cutoff value for NLR and PLR was 2.915 and 270.27,respectively.NLR at the diagnosis was found to be an independent predictor for OS and PFS by univariate and multivariate analysis,while the PLR was an independent predictor for PFS,but did not affect the OS.Conclusion:NLR and PLR may provide additional prognostic information for DLBCL patients.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2016年第2期427-432,共6页
Journal of Experimental Hematology
基金
安徽省自然科学研究重点项目(1308085MH157)
